Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P02461: Variant p.Gly267Val

Collagen alpha-1(III) chain
Gene: COL3A1
Feedback?
Variant information Variant position: help 267 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Valine (V) at position 267 (G267V, p.Gly267Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to medium size and hydrophobic (V) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In EDSVASC. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 267 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1466 The length of the canonical sequence.
Location on the sequence: help PPGIKGPAGIPGFPGMKGHR G FDGRNGEKGETGAPGLKGEN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         PPGIKGPAGIPGFPGMKGHRGFDGRNGEKGETGAPGLKGEN

Mouse                         PPGIKGPAGMPGFPGMKGHRGFDGRNGEKGETGAPGLKGEN

Rat                           PPGIKGPAGIPGFPGMKGHRGFDGRNGEKGETGAPGLKGEN

Bovine                        PPGMKGPAGMPGFPGMKGHRGFDGRNGEKGEPGAPGLKGEN
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 154 – 1221 Collagen alpha-1(III) chain
Region 95 – 1194 Disordered
Region 168 – 1196 Triple-helical region
Compositional bias 266 – 277 Basic and acidic residues
Modified residue 248 – 248 4-hydroxyproline
Modified residue 257 – 257 4-hydroxyproline
Modified residue 260 – 260 4-hydroxyproline
Modified residue 263 – 263 5-hydroxylysine; alternate
Modified residue 281 – 281 4-hydroxyproline
Modified residue 284 – 284 5-hydroxylysine
Glycosylation 263 – 263 O-linked (Gal...) hydroxylysine; alternate



Literature citations
Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type.
Pepin M.; Schwarze U.; Superti-Furga A.; Byers P.H.;
N. Engl. J. Med. 342:673-680(2000)
Cited for: VARIANTS EDSVASC; VARIANTS EDSVASC ASP-183; SER-183; VAL-192; CYS-219; VAL-225; ARG-240; VAL-243; ASP-249; VAL-249; ASP-252; ARG-252; VAL-252; VAL-255; VAL-267; VAL-321; ARG-345; ARG-417; ARG-444; GLU-489; ARG-501; VAL-519; GLU-549; GLU-552; ASP-588; ARG-636; GLU-657; ASP-660; ARG-699; VAL-738; VAL-744; TRP-828; CYS-852; VAL-879; ASP-882; ASP-900; GLU-903; VAL-909; GLU-918; CYS-924; GLU-942; VAL-966; ALA-972; THR-984; ARG-999; GLU-1011; VAL-1032; CYS-1035; ASP-1089; VAL-1098; VAL-1161; ARG-1164; GLU-1164 AND VAL-1170;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.